{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Developmental+Defect&page=43", "query": { "condition": "Developmental Defect", "page": 43 }, "page_size": 10 }, "pagination": { "page": 43, "page_size": 10, "total_count": 10802, "total_pages": 1081, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Developmental+Defect&page=44&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Developmental+Defect&page=42&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-26T08:12:53.058Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05153317", "title": "Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Years and Older", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "ELX/TEZ/IVA", "type": "DRUG" }, { "name": "IVA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 71, "start_date": "2022-01-17", "completion_date": "2026-01-29", "has_results": false, "last_update_posted_date": "2026-03-03", "last_synced_at": "2026-10-26T08:12:53.058Z", "location_count": 13, "location_summary": "Tucson, Arizona • Palo Alto, California • Aurora, Colorado + 10 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT05153317" }, { "nct_id": "NCT01721382", "title": "Treatment of Dysglycemia Using Sitagliptin in Adolescents With Cystic Fibrosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "Sitagliptin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nemours Children's Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": "20 Years", "sex": "ALL", "summary": "13 Years to 20 Years" }, "enrollment_count": 6, "start_date": "2012-11", "completion_date": "2016-06", "has_results": false, "last_update_posted_date": "2016-06-14", "last_synced_at": "2026-10-26T08:12:53.058Z", "location_count": 1, "location_summary": "Jacksonville, Florida", "locations": [ { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01721382" }, { "nct_id": "NCT04906135", "title": "Auditory Neural Function in Implanted Patients With Usher Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Usher Syndrome", "Cochlear Implantation" ], "interventions": [ { "name": "Experimental manipulation of stimulation parameters", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Ohio State University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "85 Years", "sex": "ALL", "summary": "1 Year to 85 Years" }, "enrollment_count": 29, "start_date": "2021-10-01", "completion_date": "2025-07-11", "has_results": false, "last_update_posted_date": "2025-07-29", "last_synced_at": "2026-10-26T08:12:53.058Z", "location_count": 4, "location_summary": "Boston, Massachusetts • Columbus, Ohio • Nashville, Tennessee", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04906135" }, { "nct_id": "NCT04239625", "title": "Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stargardt Disease", "Stargardt Macular Degeneration", "Stargardt Macular Dystrophy", "Autosomal Recessive Stargardt Disease 1 (ABCA4-related)" ], "interventions": [ { "name": "ALK-001", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alkeus Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "8 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "8 Years to 70 Years" }, "enrollment_count": 200, "start_date": "2019-12-20", "completion_date": "2029-12", "has_results": false, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-10-26T08:12:53.058Z", "location_count": 8, "location_summary": "Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 5 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT04239625" }, { "nct_id": "NCT00003868", "title": "Radiolabeled Monoclonal Antibody, Cyclophosphamide, and Total Body Irradiation Followed By Donor Stem Cell Transplantation in Treating Patients With Advanced Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "allogeneic bone marrow transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "iodine I 131 monoclonal antibody BC8", "type": "RADIATION" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "2 Years to 55 Years" }, "enrollment_count": 40, "start_date": "1999-02", "completion_date": "2005-03", "has_results": false, "last_update_posted_date": "2010-08-24", "last_synced_at": "2026-10-26T08:12:53.058Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003868" }, { "nct_id": "NCT03867435", "title": "Assessing Clinical Endpoints and Biomarkers in Myotonic Dystrophy Type-1 and Type 2 (ASCEND-DM)", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Myotonic Dystrophy Type-1", "Myotonic Dystrophy Type-2" ], "interventions": [], "intervention_types": [], "sponsor": "National Institute of Neurological Disorders and Stroke (NINDS)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "11 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "11 Years to 70 Years" }, "enrollment_count": 4, "start_date": "2020-02-24", "completion_date": "2021-11-02", "has_results": false, "last_update_posted_date": "2021-11-04", "last_synced_at": "2026-10-26T08:12:53.058Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03867435" }, { "nct_id": "NCT00513474", "title": "Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Graft Versus Host Disease", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms" ], "interventions": [ { "name": "busulfan", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cyclosporin-A", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "rasburicase", "type": "DRUG" }, { "name": "sirolimus", "type": "DRUG" }, { "name": "tacrolimus", "type": "DRUG" }, { "name": "allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "total-body irradiation", "type": "RADIATION" }, { "name": "fludarabine", "type": "DRUG" }, { "name": "allopurinol", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 46, "start_date": "2008-01", "completion_date": "2013-02-12", "has_results": true, "last_update_posted_date": "2017-05-25", "last_synced_at": "2026-10-26T08:12:53.058Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00513474" }, { "nct_id": "NCT05680818", "title": "Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Autosomal Dominant Hypocalcemia (ADH)" ], "interventions": [ { "name": "Encaleret", "type": "DRUG" }, { "name": "Standard of Care", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DRUG", "DIETARY_SUPPLEMENT" ], "sponsor": "Calcilytix Therapeutics, Inc., a BridgeBio company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 67, "start_date": "2023-01-06", "completion_date": "2029-08", "has_results": false, "last_update_posted_date": "2026-07-29", "last_synced_at": "2026-10-26T08:12:53.058Z", "location_count": 11, "location_summary": "Oakland, California • Aurora, Colorado • Indianapolis, Indiana + 8 more", "locations": [ { "city": "Oakland", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05680818" }, { "nct_id": "NCT00157118", "title": "Efficacy and Safety Study of Protein C Concentrate in Subjects With Severe Congenital Protein C Deficiency", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Protein C Deficiency" ], "interventions": [ { "name": "Protein C Concentrate (Human) Vapor Heated", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Baxalta now part of Shire", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 18, "start_date": "2003-08-22", "completion_date": "2005-03-17", "has_results": false, "last_update_posted_date": "2021-05-05", "last_synced_at": "2026-10-26T08:12:53.058Z", "location_count": 12, "location_summary": "Los Angeles, California • Denver, Colorado • Atlanta, Georgia + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT00157118" }, { "nct_id": "NCT02846376", "title": "Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia and Myelodysplastic Syndrome" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hackensack Meridian Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 8, "start_date": "2019-03-08", "completion_date": "2023-12-21", "has_results": false, "last_update_posted_date": "2024-11-18", "last_synced_at": "2026-10-26T08:12:53.058Z", "location_count": 1, "location_summary": "Hackensack, New Jersey", "locations": [ { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT02846376" } ] }